Expanding upon these findings, the use of GHRH antagonism, particularly with MIA-602, was successfully applied in vitro and in vivo to both AML and APL models, featuring a chemotherapy-selected derivative of the K562 cell line incubated against increasing concentrations of Doxorubicin, and a ATRA + ATO resistant NB4 subline [27–31]. Here, GHRH is linked to acute myeloid leukemia.